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Abstract: The multifunctional tissue transglutaminase has been demonstrated to act as α1-adrenergic
receptor-coupled G protein with GTPase activity in several cell types. To explore further the
pathophysiological significance of this function we investigated the in vivo effects of theα1-adrenergic
receptor agonist phenylephrine comparing responses in wild type and TG2-/- mice. Injection of
phenylephrine, but not a beta3-adrenergic agonist (CL-316,243), resulted in the long-term decline of
the respiratory exchange ratio and lower lactate concentration in TG2-/- mice indicating they preferred
to utilize fatty acids instead of glucose as fuels. Measurement of tail blood pressure revealed that the
vasoconstrictive effect of phenylephrine was milder in TG2-/- mice leading to lower levels of lactate
dehydrogenase (LDH) isoenzymes in blood. LDH isoenzyme patterns indicated more damage in
lung, liver, kidney, skeletal, and cardiac muscle of wild type mice; the latter was confirmed by a
higher level of heart-specific CK-MB. Our data suggest that TG2 as an α1-adrenergic receptor-coupled
G protein has important regulatory functions in alpha1-adrenergic receptor-mediated metabolic
processes and vascular functions.
Keywords: transglutaminase 2 KO; CLAMS; respiratory exchange ratio; heart failure; lactate
dehydrogenase; blood pressure; creatine kinase MB
1. Introduction
Tissue transglutaminase (TG2, EC 2.3.2.13) is a multi-functional protein ubiquitously found in
cells [1–3]. It possesses both protein cross-linking and guanosine 5′-triphosphate (GTP) hydrolyzing
activities [4,5]. In the presence of Ca2+, TG2 cannot bind GTP and takes on an open conformation that
covalently cross-links proteins producing isopeptide bonds between glutamine and lysine residues
through transamidase activity [6,7]. However, in GTP-bound conformation, TG2 takes on a closed
conformation and may function as a GTPase [8]. Besides, TG2 can also act as a protein disulfide
isomerase [9] and a protein kinase [10,11]. Functions of TG2 have been implicated in various biological
processes including regulation of the cytoskeleton, cell adhesion, and cell death as catalytically
active or just as an interacting protein partner [1,3,12–14]. TG2 can be detected both extracellularly
and intracellularly, and it may also localize to the nucleus and the plasma membrane of some
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cell types [1,2,15,16]. Several reports have linked TG2 functions to different types of diseases [17],
like cancer [18–20], type 2 diabetes [21], neurodegenerative disorders [22–26], and coeliac disease [27].
In the GTP-bound closed form, TG2 may act as a G protein (Ghα) transmitting signal from
α1B-adrenoceptor (α1B-AR) [28,29], oxytocin receptor [30,31], thromboxane A2α receptor [32],
and follicle-stimulating hormone receptor [33] only through direct interaction with these receptors [34].
In general, G-protein-coupled receptors (GPCRs) are known to interact with heterotrimeric G proteins;
however, TG2/Ghα forms a heterodimer with calreticulin (Ghβ) [30,34] which functions similarly to
heterotrimeric G proteins. Receptor activation switches of the TG activity by exchanging GDP to
GTP. GTP-bound TG2/Ghα dissociates from Ghβ then directly activates phospholipase Cδ1 (PLCδ1)
leading to phosphoinositide hydrolysis and an increase in intracellular Ca2+ concentrations [35–37].
Moreover, TG2/Ghα can regulate other signaling pathways including inhibition of adenylyl cyclase
(AC) activity [38] and direct activation of large-conductance Ca2+-activated K+ channels’ vascular
smooth muscle cells [39]. Signaling by TG2/Ghα is terminated when GTP is hydrolyzed to GDP by its
intrinsic GTPase activity and TG2/Ghα associated with Ghβ [34].
Strategies for unfolding the complex biological function of TG2 involve the application of
small molecules that can inhibit TG2 activities [3,40,41] and intensive studies on identification and
characterization of its substrates and interacting partners [3,42,43]. Additionally, two TG2 knock-out
(KO) mouse models have been generated using different approaches, by deleting part of exons
5 and 6, containing the active site, and intron 5 through homologous recombination [44] and by
the development of a TG2-loxP knock-in mouse, which allowed inactivation of both alleles after
cross-breeding with animals expressing Cre recombinase [45]. Considering the multifunctionality of
TG2, it is quite surprising to learn that the homozygous deletion of TG2 does not result in a lethal
phenotype. The TG2-/- animals are viable and fertile and grow up to normal size and weight with no
apparent abnormalities in development and organ functions [44,45]. The most probable explanation
for the lack of severe differences is that other transglutaminases in mammalian tissues can compensate
for the loss of TG2 [2]. However, detailed investigations of KO models have revealed that TG2
participates in the crosstalk between dying and phagocytic cells to ensure tissue integrity [46–48],
and it is required for proper differentiation and bacterial killing of neutrophils [49,50]. Ablation of TG2
results in impaired wound healing [51], autoimmunity [52], and hyperglycemia [53].
Besides, we have recently shown that TG2-/- mice have decreased cold tolerance compared to
TG2+/+ due to deficiency in adipocyte browning and low mobilization of fatty acids in gonadal
white adipose tissue [54]. The browning mechanism of white adipose tissue involves the activation
of heat-producing beige cells through the β-AR signaling pathway [55]. However, β-AR-deficient
mice can also increase the thermogenic function of their white adipose tissue in response to mild
cold exposure [56] suggesting the existence of other contributing pathways. As we measured high
levels of norepinephrine in serum samples of mice after cold exposure [54], we hypothesize that
such a mechanism could be the activation of α1-ARs. Cross-talk between α- and β-AR signaling
has been proposed in other models [57] in which TG2 as a G protein could play an important role.
If so, then activation of α1-AR must reveal physiological differences other than cold tolerance as well
between the TG2+/+ and TG2-/- strains. Although the G protein function of TG2 has been revealed in
several cell types (e.g., heart and smooth muscle cells, fibroblasts, endothelial cells, hepatocytes) [58],
its importance has not been investigated extensively in vivo yet. To substantiate the physiological
role of TG2/Ghα we injected both TG2+/+ and TG2-/- mice intraperitoneally with the specific α1-AR
agonist phenylephrine [59] or the specific β-AR agonist CL-316,243 (CL) [60] as control. While TG2+/+
and TG2-/- mice responded to CL treatment similarly, TG2-/- mice had significantly lower respiratory
exchange ratio (RER) and lower level of tissue damages especially in the heart compared to TG2+/+
animals after phenylephrine treatment. Furthermore, phenylephrine treatment has no obvious effect
on blood pressure in TG2+/+ mice in contrast to the TG2-/- ones. On the whole, our data support the
role of TG2/Ghα in maintaining regulation and responsiveness of the circulatory system.
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2. Results
2.1. Alpha1 But Not Beta3 AR Agonist Treatment Leads to Decreased Physical Activity in Both TG2+/+
and TG2-/- Mice
TG2 in some cell types can act as a G protein coupled to α1B-ARs or α1D-ARs; thus, we studied
the effect of the α1-AR agonist phenylephrine treatment on both TG2+/+ and TG2-/- mice. We also used
the β3-AR agonist CL treatment for a comparison of AR signalization pathways in the investigated
mice. First, we applied the Comprehensive Lab Animal Monitoring System (CLAMS), which is a
system of metabolic cages allowing for simultaneous measurement of several metabolic parameters
like total food and water intake, X plane cage movements (XTOT), heat production, O2 consumption
(VO2), CO2 production (VCO2), and respiratory exchange ratio (RER) [61].
There was no significant difference in the food intake between the strains throughout all the
periods of the experiment (Figure 1A,B). Interestingly, TG2-/- mice drank less water in the dark period
of the measurement day compared to the control day; however, it is important to note that when
their values were compared to the corresponding TG2+/+ values, significant differences were not
detected (Figure 1C). Besides this, TG2-/- mice drank less water in the dark period on the control day of
the CL-experiment (Figure 1D) that was not observed in the case of the phenylephrine experiment;
however, it was physiologically enough for them as it had no significant effect on the investigated
physiological parameters.
The physical activity of the strains was not different on the control day either. Intraperitoneal
injection of phenylephrine had an effect on TG2+/+ and TG2-/- mice similarly (Figure 1E) as it caused a
serious decrease in the physical activity of both strains, it was more prominent on the measurement day
only in the dark period, which is normally the active time of mice (Figure 1G). However, interestingly,
CL treatment did not affect the activity of mice (Figure 1F,H).
The strains generated the same amount of heat on the control day (Figure 1I–L); however,
phenylephrine treatment decreased the summed total heat production only in the TG2-/- strain on the
measurement day compared to the control day (light period: 181+/−35 kcal/kg vs. 241+/−7.5 kcal/kg,
p < 0.05; dark period: 238+/19 kcal/kg vs. 312+/−20 kcal/kg, p < 0.05; Figure 1I,K). Furthermore, after
injection of CL, the TG2+/+ mice increased heat production in the light period and the TG2-/- animals in
the dark period on the measurement day, but it is more important that there were no differences when
the strains were compared to each other in the investigated periods (Figure 1K,L).
2.2. Alpha1 But Not Beta3-AR Agonist Treatment Results in a Decrease of the Respiratory Exchange Ratio in
TG2-/- Mice Compared to TG2+/+ Animals
VO2 values of the strains were the same both in the light and dark periods of the control day
without any treatments (Figure 2A–D). Phenylephrine induced a decrease in VO2 levels after absorption
in the case of both strains. Nonetheless, TG2+/+ animals set back the normal value within the light
period after the treatment and recovered, but the VO2 of TG2-/- mice remained lower (Figure 2A).
In contrast, CL treatment evoked a little increase of VO2 of the strains, however, in a very similar way
when they were compared to each other (Figure 2B). We calculated the total VO2 for the light and dark
periods before and after the phenylephrine treatment and we found that the values of TG2+/+ mice
remained unchanged. Although the VO2 values of TG2-/- animals were lower after the treatment both
in the light and dark periods correlated to their corresponding control periods, there were no significant
differences when we compared the values of TG2-/- mice to TG2+/+ ones (Figure 2C). Meanwhile,
CL treatment did not cause any significant changes in the total VO2 values of the strains (Figure 2D).
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Figure 1. Alpha1 but not beta3 adrenoreceptor (AR) agonist treatment leads to decreased physical 
activity in both TG2+/+ and TG2-/- mice. Total (A, B) food intake and (C, D) water consumption are 
shown before (CTRL) and after (A,C) phenylephrine or (B,D) CL-316,243 (CL) treatment for both in 
the light (9:03 a.m.–6:00 p.m.) and the dark (6:01 p.m.–6:00 a.m.) periods. Mean values of physical 
activity are presented before and after (E) phenylephrine and (F) CL treatments. Arrowheads show 
the time point (9:00 a.m.) when the compounds were injected intraperitoneally (60 nM/g body 
weight). Day (□) and night (■) periods are indicated on the “X” axes (n = 6). Total physical activity is 
also presented for (G) phenylephrine and (H) CL investigations before (CTRL) and after the 
treatments both in the light and dark periods. (I, J) Mean values of heat generation and (K, L) total 
Figure 1. l t t et re rece t r ( ) agonist treatment leads to decreased physical
activit i bot +/+ and TG2-/- mice. Total (A,B) f od intake and (C,D) water consumption are
shown before (CTRL) and after (A,C) phenylephrine or (B,D) CL-316,243 (CL) treatment for both in the
light (9:03 a.m.–6:00 p.m.) and the dark (6:01 p.m.–6:00 a.m.) periods. Mean values of physical activity
are presented befor and aft r (E) ph nyle ri e and (F) CL treatments. Arrowheads s ow the time
point (9:00 a.m.) when the compounds were injected intraperitoneally (60 nM/g body weight). Day ()
and night () perio s are indicat d on th “X” x s (n = 6). Tot l physical activity is also presented
for (G) ph yleph ine and (H) CL inv stigations before (CTRL) a d after the treatments bo h in the
light and dark periods. (I,J) Mean values of heat generation nd (K,L) to al heat ge eration are shown
for (I,K) phenylephrine and (J,L) CL experiments. Columns represent the mean values ± SD (n = 6).
Statistical analyses were carried out using GraphPad Prism 7.0 version, by two-way ANOVA (Tukey’s
multiple comparison test; * p < 0.05, ** p < 0.01 and *** p < 0.001).
Similarly to VO2, the VCO2 values of the strains were the same both in the light and dark control
periods (Figure 2E–H). Phenylephrine treatment caused a decline in VCO2 levels of the strains equally,
and then they started to increase gradually to the normal levels. However, the value of TG2-/- mice
remained a little lower after the treatment (Figure 2E). Interestingly, the CL treatment did not affect the
VCO2 values of the strains, which remained the same (Figure 2F). We also calculated the total VCO2
for the light and dark periods before and after phenylephrine treatment and found that the values of
TG2+/+ mice remained unchanged. Though similarly to VO2, the VCO2 values of TG2-/- animals were
lower both in the light and dark periods after phenylephrine treatment compared to their analogous
control periods, there were no significant differences when we compared them to the values of TG2+/+
mice (Figure 2G). Like in the case of VO2, the CL treatment did not cause any significant changes in
total VCO2 values of the strains (Figure 2H).
RER values (VCO2/VO2) of TG2-/- and TG2+/+ mice were very similar both in the light and
the dark periods of the control day before phenylephrine treatment (Figure 2I–K). After absorption
of intraperitoneally injected 60 nM/g body weight phenylephrine the RER values of both strains
significantly decreased similarly in the first part of the light period on the treatment day demonstrating
that the treatment affected. However, while the RER value of the TG2+/+ strain started to increase
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constantly in the second part of the light period, and in the following dark period it reached the level
detected before the treatment, RER remained still low in the case of TG2-/- mice (Figure 2I). This resulted
in significantly lower RER value of TG2-/- animals compared to TG2+/+ ones in the dark period on the
measurement day (TG2-/-: 0.79+/−0.03 vs. TG2+/+: 0.89+/−0.05, p < 0.05; Figure 2K). After absorption of
intraperitoneally injected 60 nM/g body weight CL in the first part of the light period on the treatment
day, the RER values of both strains promptly dropped down demonstrating the physiological effect of
CL and then started to increase equally in the second part of the light period (Figure 2J). Consequently,
while the RER values of both strains were significantly lower in the dark period on the measurement
day compared to the control dark period, there was no difference between the strains (Figure 2L).Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 5 of 19 
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(6:01 p.m.–6:00 a.m.) periods. Columns represent the m an values ± SD (n = 6). Statistical nalyses
were carried out using GraphPad P ism 7.0 ve sion, by two-way ANOVA (Tukey’s multiple co parison
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2.3. Alpha1-AR Agonist Treatment Results in Lower Blood Lactate Levels in TG2-/- Mice
Blood glucose levels of TG2+/+ and mice TG2-/- were the same on the control day both in the light
and the dark periods (Figure 3A), and phenylephrine injection did not lead to changes (Figure 3B).
Both insulin and glucagon levels were found similar in the serum samples of the strains obtained at the
same time point after the treatment (Figure 3C,D). Furthermore, serum concentrations of lipid fractions
cholesterol (C), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol
Int. J. Mol. Sci. 2020, 21, 3865 6 of 18
(HDL-C), triglyceride (TG), and free fatty acid (FFA) did not differ after phenylephrine treatment either
in TG2+/+ or TG2-/- mice (Figure 3E). Interestingly, however, lactate concentration was significantly
higher in the serum of TG2+/+ mice compared to TG2-/- ones (12.7+/−0.64 mM vs. 10.74+/−1.4 mM,
p < 0.05) 13 h after the phenylephrine treatment (Figure 3E).
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Figure 3. Blood metabolic parameters of TG2+/+ and TG2-/- mice after phenylephrine treatment. (A)
Blood glucose levels of TG2+/+ and TG2-/- mice on the control day. (B) Blood glucose levels of TG2+/+
and TG2-/- mice after phenylephrine treatment. Day () and night () periods are shown on the “X”
axes. Arrowhead indicates the time point of phenylephrine injection. The experiments were carried
out according to the scheme presented in Figure 4A. (C) Insulin concentration in serum samples of
TG2+/+ and TG2-/- mice 13 h after phenylephrine treatment. (D) Glucagon concentration in serum
samples of TG2+/+ and TG2-/- mice 13 h after phenylephrine treatment. (E) Serum lipid and lactate
concentration values of mice 13 h after phenylephrine treatment. C: cholesterol, LDL-C: low-density
lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol, TG: triacylglycerol, FFA: free
fatty acid. Columns or measurement points represent the mean values ± SD. Statistical analyses were
performed using Student’s t-test (n = 5, *p < 0.05).
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Figure 4. Phenylephrine treatment does not decrease tail blood pressure of TG2-/- mice in contrast to
TG2+/+. (A) Schematic pres ntation of the experiments. Tail blood pressure ( BP) and heart rate (HR)
were measured at the same time points of both the acclimation day and the control day. On the third
m asurement ay, mice w re injected intraperitone lly with 60 nM/g body weight phenylep rine at
11:30 a.m. Systolic pressure on the ontrol d y (B) and the measurement day (C); and diastolic pressure
on the control day (D) and on the measurement day (E) are pres nted separatel . (F HR values on
the control day (G) HR values on the measurement day. Day () and night () periods are shown on
the “X” axes. Arrowhe ds indicate th time point of phenylephrine injection. Measurement points
represent t e mean values ± SD. Statist l analyses were carried out us g Student’s t-te t (n = 5,
* p < 0.05, ** p < 0.01).
2.4. Alpha1-AR Agonist Has a Lowering Effect on Tail Blood Pressure of TG2+/+ But Not TG2-/- Mice
Comparing TG2+/+ and TG2-/- mice, we found that both their tail blood pressure (TBP) and heart
rate (H ) values were very similar before the treatment (Figure 4B,D,F). Oddly, at the first measurement
time point of the experiment, that was 30 min after the injection of phenylephrine, we could not record
both systolic and diastolic pressure of all the investigated TG2+/+ mice in contrast to TG2-/- animals
in which detection of TBP was successful. Besides, while TBP values of the strains were similar in
the light period, systolic pressure values and two of the three detected diastolic pressure values were
significantly lower in TG2+/+ animals compared to TG2-/- mice in the dark period (Figure 4C,E). As a
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result, TBP values of TG2-/- mice remained unchanged after the phenylephrine treatment, while those
of TG2+/+ animals were lower in the dark period compared to the control day (Figure 4C vs. Figure 4B;
Figure 4E vs. Figure 4D). Furthermore, we did not detect differences in HR values of the strains except
the second measurement of the dark period after the treatment, when TG2+/+ showed lower levels
(Figure 4F,G).
2.5. Alpha1-AR Agonist Evokes a Higher Level of Tissue Damages Monitored by Lactate Dehydrogenase (LDH)
Release in TG2+/+ than in TG2-/- Mice
Serum samples of TG2+/+ mice isolated 13 h after the phenylephrine treatment contained a
significantly higher level of LDH compared to TG2-/- animals’ (725+/−34 U/L vs. 1142+/−58 U/L,
p < 0.001; Figure 5A). Electrophoretic separation and densitometry revealed that four out of the five
isoenzymes were present in larger quantities in TG2+/+ samples than in TG2-/- ones, namely LDH1,
LDH2, LDH4 and LDH5 (Figure 5B,C). The KO/wild type (WT) ratios of the isoenzymes LDH2, LDH4,
and LDH5 were similar. However, the KO/WT ratio of LDH1, which may represent a cardiac-specific
component, was lower (11%+/−2% vs. 17%+/−1%, p < 0.05; Figure 5D). Moreover, the level of CK-MB
was also higher in the serum samples of TG2+/+ mice compared to TG2-/- animals’ (235+/−30 U/L vs.
158+/−16 U/L, p < 0.01; Figure 5E).
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Figure 5. Phenylephrine treatment results in a lower degree of tissue damages reflected in changes
of LDH isoenzyme patterns in TG2-/- mice compared to TG2+/+. (A) Total lactate dehydrogenase
isoenzyme (LDH) enzyme activity values in serum samples of mice 13 h after the phenylephrine
treatment. (B) Agarose gel electrophoretic separation of serum lactate dehydrogenase isoenzymes
(LDH-1 to LDH-5) of TG2+/+ and TG2-/- mice (lanes: 1–3 TG2+/+, lanes: 4–6 TG2-/-, lane 7: human
control serum). (C) Enzyme activity levels of LDH isoenzymes in serum samples of mice 13 h after the
phenylephrine treatment. (D) Relative LDH isoenzyme activity values in serum samples of mice 13 h
after the phenylephrine treatment. (E) CK-MB activity levels in serum samples of mice 13 h after the
phenylephrine treatment. Columns represent the mean values ± SD. Statistical analysis was performed
using Student’s t-test (n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001).
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3. Discussion
The deletion of the multifunctional TG2 does not cause severe phenotype in mice. It is generally
explained by the fact that other members of the TG family can be expressed in cells and they may
substitute most of the lacking functions of TG2. However, the other mammalian TG do not bind
GDP/GTP, consequently, they cannot cover the G protein function of TG2. Nonetheless, other classical
G proteins are likely present in TG2-expressing cells, which can assume the role of TG2 as a G protein.
Therefore, more severe alterations have been expected in viable TG2-/- mice only under certain stresses
and pathological conditions [2].
Phenylephrine is a sympathomimetic amine with epinephrine-related chemical structure selectively
binds to α1-ARs and activates them [62]. The G protein-coupled ARs have a 7-transmembrane domain
structure, and in general, they can mediate contraction and hypertrophic growth of smooth muscle
cells. ARs have three subtypes, which share approximately 75% homology: α1A, α1B, and α1D.
Phenylephrine appears to act similarly on all three receptor subtypes [63]. It is well-recognized that
TG2 may act as a Ghα protein binding to α1B-ARs or α1D-ARs, but not α1A-ARs [64], independently
from its transamidation activity. Therefore, we investigated the effect of phenylephrine treatment on
TG2+/+ and TG2-/- mice and used CL β3-AR agonist for comparison.
Comparing TG2+/+ and TG2-/- mice we found striking differences in RER (ratio of CO2 production
and O2 consumption) values especially in the dark period, several hours after the phenylephrine
treatment. In the case of TG2+/+ animals, RER dropped, then started to increase gradually from
about 0.8 to the level close to 1, which was detected as a control value before injection in both strains.
Meanwhile, RER of TG2-/- mice did not start to increase, after dropping and remained low even in
the dark period after the treatment. The dark period is normally the active phase of mice, but the
development of this deviation is unrelated to this as there was no difference in the physical activity
of the animals, which decreased and remained significantly lower for both strains even in the dark
period after the injection. It is generally accepted that RER indicates which type of fuel is being
preferably metabolized. It ranges from 1.0 where pure glucose is oxidized to 0.7 where pure FFA is
oxidized [65]. Accordingly, TG2+/+ and TG2-/- mice gained energy mainly from the degradation of
carbohydrates before the phenylephrine injection, but after the treatment, they immediately started to
utilize FFAs in our experiments. Interestingly, however, TG2-/- animals continued to break down FFAs
for a much longer time while TG2+/+ mice started to utilize carbohydrates increasingly. The observed
approximately 0.1 difference in the RER values after the phenylephrine treatment on a maximum
0.3 scale (from 0.7 to 1.0) reflects a quite different metabolism of the whole organism kept on the same
diet and is a surprising finding worth investigating further. It is important to note that activation
of both α1A- and α1B-ARs can increase whole-body fatty acid oxidation resulting in a decrease of
RER [66]. TG2-/- animals reached the RER values of TG2+/+ mice later at the end of the recovery stage,
at about 30 h after the treatment (data not shown). These results indicate that TG2 functioning as a
Ghα protein in adrenergic receptor signaling may play a role in determining the balance between
carbohydrate and fatty acid oxidation.
We applied CL, a specific β3-AR agonist as a control for the α1-AR agonist phenylephrine.
This receptor is located mainly in adipose tissue where it can enhance lipolysis [67]. Consequently,
the injection of CL resulted in the prompt decrease of RER values in both TG2-/- and TG2+/+ mice, which
started to increase gradually in a similar way during the dark period. Other metabolic parameters of
the strains were also very similar which shows that TG2 has no role in signal transduction regulated
by β3-AR. B3-AR is also involved in the regulation of thermogenesis in skeletal muscle [68] and fat
tissues [69]; but, we did not detect differences in heat production of the strains after β3-AR stimulation.
However, the generation of heat decreased in TG2-/- mice and was lower after phenylephrine injection
both in the light and the dark periods. We have reported that TG2-/- mice have decreased tolerance
to cold exposure [54], and this result may suggest that TG2 potentially affects heat production as an
α1B-AR-coupled G protein in mice.
Int. J. Mol. Sci. 2020, 21, 3865 10 of 18
As α1-ARs may have roles in the regulation of various metabolic processes [66,70,71], first we
measured blood glucose levels of strains and found them to be similar and normal [72,73] both before
and after the phenylephrine injection. Phenylephrine increased glucagon levels compared to the
normal values through an unknown subtype of α1-AR as it is described [73], but its levels in the
plasma of TG2-/- and TG2+/+ animals were similar 13 h after the phenylephrine treatment when the
difference in RER values was prominent. These results together with the obtained data of lipid fractions
suggest that the most important fuels for cellular metabolism were available in excess for mice fed ad
libitum, and their different utilization could result in the dissimilar RER values as discussed above.
Phenylephrine is thought to act quickly, within some minutes after absorption, and its estimated
half-life is about 2.1–3.4 h [74] as it is extensively metabolized by monoamine oxidase [75]. Therefore,
the observed difference in RER values probably was not caused by the presence of phenylephrine
directly, but rather long-term effects induced by this agonist.
It has been reported that α1B-AR KO mice had normal blood glucose and insulin levels, but
elevated leptin concentrations in the fed state [71]. Leptin is known to stimulate glucose uptake
and beta-oxidation by activating AMP-activated protein kinase (AMPK) especially in the skeletal
muscle [76]. The activation of AMPK can be mediated by two different mechanisms: firstly, by the
direct effect of leptin, or secondly, by its indirect effect through the hypothalamic sympathetic nervous
system and α1B-AR mechanism [71,77]. The activation of AMPK by leptin leads to phosphorylation
and inhibition of acetyl-CoA carboxylase (ACC) and results in the stimulation of fatty acid oxidation
by disinhibition of carnitine palmitoyltransferase 1 (CPT1) in muscle [76]. If TG2 can act as Ghα,
then signal transduction of α1B-AR can be deficient at least in part in TG2-/- mice resulting in a higher
level of leptin and lower RER, as we observed, compared to TG2+/+ after phenylephrine treatment.
Higher lactate levels in the plasma of TG2+/+ mice probably indicated that they utilized more glucose
than TG2-/- ones.
Phenylephrine is a potent vasoconstrictor that increases cardiac preload without any important
direct effect on cardiac myocytes. It can increase blood pressure keeping a slow heart rate through
stimulation of vascular baroreceptors. Thus, phenylephrine is generally administered for patients
with normal cardiac function but with clinically significant hypotension caused by vasodilation [78].
Phenylephrine can cause pronounced vascular adverse effects, including increases in both systolic and
diastolic BP [79], therefore we measured TBP of the mice. We found that both systolic and diastolic
BP of TG2-/- animals were similar to TG2+/+ values on the control day before the treatment. It is
important to note that phenylephrine is known to cause contraction of tail caudal arteries making
impossible the detection of TBP until the compound is degraded [80]. Indeed, we could not detect TBP
of TG2+/+ mice at the first time point 30 min after the phenylephrine injection. However, TBP could
be measured in all investigated TG2-/- animals, and their TBP values were comparable with those
found at the control day suggesting absence or just low level of contraction in their caudal arteries
at the first time point of the measurement in the absence of TG2. Decreased BP response in α1B-AR
KO mice, similar to our finding in TG2-/- mice, was demonstrated suggesting that this type of AR
is an important mediator of BP [81]. Consequently, if TG2 can act as an α1B-AR-coupled Ghα, then
this function could lead to increased smooth muscle cell tone [29,82–84] and explain why we did not
observe vasoconstriction in the tail of TG2-/- mice. Furthermore, it was shown that TG2 modulated
vascular function through its crosslinking-independent manner as well, and TG2-/- aorta was found to
be stiffer compared with TG2+/+ [85]. Interestingly, the long-term effect of phenylephrine was also
apparent in our study, as systolic BP of TG2+/+ animals remained significantly lower in the dark period,
and their diastolic BP was also lower at two measurement points out of the three in this period.
Because of its vasoconstrictive effect, phenylephrine can cause severe necrosis in tissues [78].
LDH is a soluble cytoplasmic enzyme that is present in almost all cells and released into extracellular
space when the plasma membrane is damaged during necrosis [86]. Quantifying the LDH activity in
the serum samples indicates the degree of tissue damages [87], therefore, we measured the LDH activity
in serum samples of the strains to compare the level of necrosis caused by phenylephrine treatment.
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Total LDH activity was pathologically high in both strains compared to normal values 13 h after the
injection [88], but it was significantly higher in TG2+/+ samples compared to TG2-/- sera. The tetrameric
LDH is composed of two types of subunits, the LDH-M, and the LDH-H proteins. These two subunits
can form five possible isoenzymes (LDH1-5) that are enzymatically similar but show different tissue
distribution. Consequently, the pathological appearance of different isoenzymes in serum can indicate
in which tissue or organ the damage occurred [89]. Electrophoretic separation and quantitation of
LDH isoenzymes revealed that phenylephrine treatment caused damages in several organs, but these
were higher in TG2+/+ mice. The level of LDH1 characteristic for damage in cardiac muscle and
kidney, LDH2 for kidney, LDH4 for brain and lung, and LDH5 for liver and skeletal muscle were
higher in TG2+/+ mice-derived samples compared to TG2-/- ones, respectively. When we calculated the
relative LDH isoenzyme activity values in serum samples of mice, we found that compared to the other
isoenzymes, the elevation of LDH1 level was the most prominent in TG2+/+ samples suggesting that
the highest difference in organ damages is in the heart. To confirm that the heart was damaged more
seriously in TG2+/+ animals, we also checked CK-MB activity in sera which is a much more specific
marker for heart [90] and found that it was also significantly higher in TG2+/+ animals compared to
TG2-/- mice. Although our data indicate that the heart was damaged more seriously in TG2+/+ animals
after phenylephrine treatment, it is important to note that there was no difference in the HR values of
the mice, except at a single time point of the experiments in the dark period, which suggest that heart
damages did not cause functional disorders in the investigated period. The role of TG2 as a G protein
in the maintenance of normal cardiovascular function has not been clarified yet [45].
4. Materials and Methods
4.1. Materials
All chemicals were from Sigma-Aldrich (Munich, Germany) except indicated otherwise.
4.2. Mice, Treatments and Obtained Samples
TG2 deficient mice (TG2-/-) [44] and WT littermates (TG2+/+) with C57BL/6J genetic background
were obtained from heterozygous breeding couples and were genotyped in the Animal Core Facility at
the University of Debrecen. Mice were housed separately, had ad libitum access to water and chow, and
were kept in a 12 h light (6 a.m. to 6 p.m.) and 12 h dark (6 p.m. to 6 a.m.) cycle at 22 ± 1 ◦C. Body mass
of 18-week old males was measured and they were injected intraperitoneally with 60 nM/g body weight
phenylephrine (specific alpha1-AR agonist) [91] or CL-316,243 (specific beta-AR agonist) [92]. Mice were
anesthetized and blood was collected from the heart, serum was obtained and stored at −80 ◦C. All the
animal experiments were approved by the Animal Care and Use Committee of University of Debrecen
(DEMAB) project IDs 14/2010/DEMAB and 1/2014/DEMAB (approved on 18/01/2010 and 26/11/2014,
respectively) according to national, and EU ethical guidelines.
4.3. Indirect Calorimetry
Measurements were performed using the Comprehensive Lab Animal Monitoring System (CLAMS,
Columbus Instruments, Columbus, OH, USA). Six TG2+/+ males and six TG2-/- males on a chow
diet were placed individually in chambers for 4 consecutive days at ambient temperature (22 ◦C).
Mice were provided free access to food and water, in a 12 h light (6 a.m. to 6 p.m.) and 12 h dark
(6 p.m. to 6 a.m.) cycle. Measurements were made in 8 min intervals after the initial 18–20 h
acclimation period. Physical activity was monitored in the X planes (XTOT) using an infrared light
beam. Measurements for animals’ oxygen consumption (VO2) and carbon dioxide production (VCO2)
were used to estimate the respiratory exchange ratio (RER). Food intake and heat generation were also
measured in metabolic chambers [93]. The acclimation period was followed by control measurement
for 24 h without treatment. Then, mice were injected intraperitoneally with 60 nM/g body weight
phenylephrine (specific alpha1-AR agonist) or CL-316,243 (specific beta-AR agonist) and investigated
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for an additional 24 h. The average and related standard deviation of obtained values were calculated
and statistically analyzed using two-way ANOVA. In the end, all the mice survived the experiment
and recovered completely.
4.4. Blood Pressure Measurement
The CODA Non-Invasive Blood Pressure system (a tail-cuff method, Kent Scientific Corporation,
Torrington, CT, USA) was used to measure the blood pressure (BP) in mice as described [94,95].
The CODA tail-cuff system uses volume pressure recording (VPR) to detect the blood pressure by
determining the tail blood pressure (TBP). Special attention is afforded to the length of the occlusion
cuff to derive the most accurate blood pressure readings. Three different blood pressure parameters
were measured; systolic and diastolic blood pressure and heart rate. Measurements were carried out on
awake mice. The acclimation period was followed by control measurements for 24 h without treatment.
Then, mice were injected intraperitoneally with 60 nM/g body weight phenylephrine (specific α1-AR
agonist) and investigated for an additional 13 h.
4.5. Detection of Blood Metabolic Parameters
Blood glucose concentration was measured as previously described [53]. Serum samples were
prepared from the plasma of mice collected 13 h after phenylephrine treatment through heart
punctuation. Total cholesterol (C), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), triglyceride (TG), free fatty acid (FFA), and lactate levels were determined by
colorimetric enzyme assays (Cobas6000, Roche Ltd., Mannheim, Germany) and free fatty acid (FFA)
by a standard laboratory assay [96,97]. Insulin content was detected using Mouse Insulin ELISA Kit
(Mercodia, Sweden), glucagon level was measured using Glucagon EIA Kit (Sigma-Aldrich Chemie
GMBH, Darmstadt, Germany) according to the manufacturers’ instruction from 5–5 TG2+/+ and TG2-/-
serum samples.
4.6. Detection of LDH and CK-MB
LDH activity was determined with a UV kinetic method recommended by IFCC [98], and CK-MB
activity was measured with the immunoinhibition UV kinetic method on the Cobas-501 analyzer
(Roche) [99,100]. LDH isoenzymes were separated on Hydragel ISO-LDH with electrophoresis and the
amounts of isoenzymes were determined by densitometry (Sebia Hydrasys, Sebia, Lisses, France) [101].
4.7. Statistical Analyses
GraphPad Prism version 7.0 and Microsoft Excel 14.0 were used for data interpretation and
calculation of significance. Results are expressed as the mean ± SD for the assays indicated.
For comparing groups Student’s t-test and two-way ANOVA (Tukey’s multiple comparison test)
were used. Values of p < 0.05 were considered statistically significant with *, ** and *** corresponding
to p < 0.01 and p < 0.001, respectively.
5. Conclusions
In this study, we have investigated the pathophysiological effects of the α1-AR agonist
phenylephrine in TG2-/- mice and found pieces of evidence that that TG2 participates inα1-AR-regulated
biological processes and obtained proofs in vivo that it regulates metabolic and vascular functions.
Although our data suggest that TG2 acts as an α1B-AR-coupled G protein, further studies have to
reveal details of the underlying molecular mechanisms.
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